1	Molecular PD-L1 PET/CT Imaging with ⁸⁹ Zr-atezolizumab to Monitor Immune				
2	Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II				
3	diagnostic imaging trial.				
4	Short title: ⁸⁹ Zr-atezolizumab PET-imaging in metastatic triple negative breast cancer				
5					
6	Renske Altena ^{1,2} *, Thuy A. Tran ^{2,3} , Una Kjällquist ^{1,2} , Mattias Karlsson ⁴ , Jonathan Siikanen ³ , Emma				
7	Jussing ^{2,3} , Antonios Tzortzakakis ^{4,5} , Olof Jonmarker ^{5,6} , Rimma Axelsson ^{4,7} , Jonas Bergh ^{1,2}				
8					
9	Author affiliations				
10	1. Medical Unit Breast, Endocrine Tumors and Sarcoma, Theme Cancer, Karolinska University Hospital,				
11	Stockholm, Sweden.				
12	2. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.				
13	3. Department of Radiopharmacy, Karolinska University Hospital, Solna, Sweden				
14	4. Department of Medical Radiation Physics and Nuclear Medicine, Functional Unit of Nuclear				
15	Medicine, Karolinska University Hospital, Huddinge, Sweden				
16	5. Division of Radiology, Department for Clinical Science, Intervention and Technology (CLINTEC),				
17	Karolinska Institutet				
18	6. Department of Radiology, Functional Unit of Medical Diagnostics, Karolinska University Hospital,				
19	Solna, Sweden				
20	7. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden				
21					
22	* Correspondence: Renske Altena MD PhD, Medical Unit Breast, Endocrine tumors and Sarcoma,				
23	Karolinska University Hospital Solna, Sweden, Email: renske.altena@ki.se, Telephone: +46 8 123 755				
24	18				
25	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.				
	no re. This proprint reports new research that has not been certained by peer review and should not be used to guide chilical practice.				

26 Abstract

27 Background

49

28 Immune checkpoint inhibitors (Programmed Death Ligand 1 [PD-L1] and Programmed Death 1 [PD-1] 29 antibodies) are approved for the first line treatment of metastatic and irresectable triple negative 30 breast cancer (mTNBC) with immunohistochemical (IHC) PD-L1 positivity on a tumor biopsy, and 31 combined with a chemotherapy backbone. Intra- and interlesional as well as spatial heterogeneity in 32 PD-L1 expression as well the invasive nature of tumor biopsies poses disadvantages of this method of 33 selecting patients for the addition of PD-L1/PD-1 antibodies. Our study hypothesis is that whole body 34 Positron Emission Tomography with computed tomography (PET/CT) imaging with a PD-L1 specific 35 radiotracer could be a more reliable biomarker approach for the selection of patients with mTNBC 36 who benefit from the addition from PD-L1/PD-1 antibodies. 37 38 Methods 39 In the phase II "Molecular PD-L1 PET/CT Imaging with ⁸⁹Zr-atezolizumab to Monitor Immune 40 Responses in metastatic Triple Negative Breast Cancer" (MIMIR-mTNBC) trial, treatment enrichment 41 for checkpoint inhibitors is done by a baseline ⁸⁹Zr-atezolizumab PET/CT followed by a tumor biopsy to 42 determine PD-L1 by IHC. Patients with a PD-L1 positive tumor on biopsy and/or PET are treated with 43 chemotherapy + atezolizumab. The primary aim of the study is to assess the level of statistical 44 agreement between the reference standard (PD-L1 IHC) compared to the experimental method (PD-45 L1 PET) by means of Cohen's kappa coefficient. The trial is registered at Clinicaltrials.org with number 46 NCT05742269. 47 48 Discussion

50 atezolizumab to complement or replace the assessment of PD-L1 status by means of IHC on a tumor

The results of the MIMIR-mTNBC trial are expected to reveal the possibility of PD-L1 PET with ⁸⁹Zr-

51 biopsy, and as a possible method to select patients with mTNBC that benefit from the addition of

52	atezolizumab to a chemotherapy backbone. This non-invasive tool may provide a method that reveals				
53	relevant information about hete	erogeneity in the expression of the target of treatment.			
54					
55	Trial registration: NCT05742269	9, Trial registered on February 23 rd , 2023, at clinicaltrials.gov			
56	Keywords: Metastatic triple neg	gative breast cancer, PD-L1, ⁸⁹ Zr-atezolizumab, molecular imaging,			
57	predictive biomarker				
58	Data Availability: All relevant da	ta needed to replicate the trial can be found in the study protocol and			
59	through communication with th	ne Principal Investigator.			
60	Funding: This study is funded by	y a grant from the Swedish Cancer Society (Dnr 19 0189 Us) to			
61	Professor Jonas Bergh, Radiumł	nemmets Research Fund 2020 to Renske Altena, Swedish Breast cancer			
62	Society 2020 to Renske Altena a	and Percy Falk Foundation to Professor Rimma Axelsson. Atezolizumab,			
63	SP142 IHC antibodies and Found	dation One CDx is kindly provided by Roche AB. The funders do not			
64	have a direct role in the design	of the study and collection, analysis, or interpretation of data.			
65	Competing interests: The authors have declared that no competing interests exist.				
66					
67					
68					
69	Word count (core text)	3,567			
70	References	18			
71	Figures	2			
72	Tables	2			
73					
74					

76 Introduction

77	The current standard of care for triple negative breast cancer includes the combination of immune
78	checkpoint inhibitors (ICI) with a chemotherapy backbone, both in the neo-adjuvant and metastatic
79	setting. For patients with metastatic or irresectable triple negative breast cancer (mTNBC)
80	atezolizumab (Programmed Death Ligand 1 [PD-L1]) and pembrolizumab (anti Programmed Death [PD-
81	1]) are approved for patients with immunohistochemical (IHC) PD-L1 expression in a tumor biopsy
82	according to specific criteria with a companion diagnostic IHC antibody, based on data from the
83	IMpassion130 and Keynote355 trials respectively (1-4).
84	
85	In the IMpassion130 study, patients with mTNBC were treated with nab-paclitaxel atezolizumab or
86	placebo. A statistically significant improvement in progression free survival (PFS) and a clinically
87	meaningful improvement in overall survival (OS) for patients whose tumor had over 1% PD-L1
88	expression on tumor infiltrating lymphocytes was found, with a numeric improvement in median PFS
89	of 2.5 months (7.5 months and 5.0 months, respectively with a hazard ratio [HR] of 0.62; 95%
90	confidence interval [CI] 0.49-0.78; P<0.001) and a median OS of almost 10 months (25.0 months and
91	15.5 months, respectively, with a HR of 0.62; 95% CI, 0.45-0.86) (1,2). At the final OS update, this
92	benefit in overall survival landed at 7.5 months in the PD-L1 positive subgroup (HR, 0.67; 95% CI, 0.53-
93	0.86) (2).
94	In the Keynote355 study, patients with a Combined Positive Score (CPS with the pharmDx test) of 10
95	or more treated with pembrolizumab plus chemotherapy (either nab-paclitaxel; paclitaxel; or
96	gemcitabine plus carboplatin) had an improvement in median PFS of little over 4 months (9.7 months
97	and 5.6 months respectively, HR for progression or death, 0.65, 95% CI 0.49–0.86) (3), and an increase
98	in OS for patients in the CPS-10 subgroup was from 16.1 months in the placebo–chemotherapy group
99	to 23.0 months in the pembrolizumab–chemotherapy group (hazard ratio for death, 0.73; 95% CI
100	0.55-0.95) (4).

101

102	There is an urgent clinical need to establish reliable and reproducible therapy-predictive biomarkers
103	for ICI in solid tumors, in order to optimize the risk-benefit balance on an individual and societal level.
104	Up to now, for mTNBC the only approved biomarker for the addition of ICI to a chemotherapy
105	backbone is PD-L1 expression on a tumor biopsy according to pre-defined criteria as mentioned above
106	[5]. However, this method also has a suboptimal performance, as concluded in a systematic review
107	and meta-analysis across all solid tumors [6]. For TNBC, several alternative candidate biomarkers have
108	been proposed but have yet to be validated thoroughly enough to be implemented in clinical practice
109	and replace PD-L1 IHC on a tumor biopsy [7]. It has been unequivocally described that PD-L1
110	expression can change over time in primary and metastatic breast cancer, as well as have varying
111	levels of expression in metastases in different organs [8], which limits even further the therapy-
112	predictive role of PD-L1 IHC for the benefit of ICIs for patients with TNBC. Interestingly, PD-L1 status in
113	the primary tumor has no therapy-predictive role for the addition of pembrolizumab to a
114	chemotherapy backbone in the neoadjuvant treatment setting, as was observed in the Keynote522
115	trial [9].
116	
117	Positron Emission Tomography (PET) imaging with receptor-specific tracers can provide, in a non-
	Position Emission fomography (PET) imaging with receptor-specific tracers can provide, in a non-
118	invasive manner, information on whether the target for treatment exists. At the same time, PET
118 119	
	invasive manner, information on whether the target for treatment exists. At the same time, PET
119	invasive manner, information on whether the target for treatment exists. At the same time, PET enables quantification of the target in the whole body in real-time and with a high degree of accuracy.
119 120	invasive manner, information on whether the target for treatment exists. At the same time, PET enables quantification of the target in the whole body in real-time and with a high degree of accuracy. Several radiotracers representing treatment targets in breast cancer management have been
119 120 121	invasive manner, information on whether the target for treatment exists. At the same time, PET enables quantification of the target in the whole body in real-time and with a high degree of accuracy. Several radiotracers representing treatment targets in breast cancer management have been evaluated, e.g. tracers visualizing the Estrogen Receptor (ER) and Human Epidermal growth factor
 119 120 121 122 	invasive manner, information on whether the target for treatment exists. At the same time, PET enables quantification of the target in the whole body in real-time and with a high degree of accuracy. Several radiotracers representing treatment targets in breast cancer management have been evaluated, e.g. tracers visualizing the Estrogen Receptor (ER) and Human Epidermal growth factor Receptor 2 (HER2). 18F-FES, representing ER-positive lesions, is a currently FDA approved tracer that
 119 120 121 122 123 	invasive manner, information on whether the target for treatment exists. At the same time, PET enables quantification of the target in the whole body in real-time and with a high degree of accuracy. Several radiotracers representing treatment targets in breast cancer management have been evaluated, e.g. tracers visualizing the Estrogen Receptor (ER) and Human Epidermal growth factor Receptor 2 (HER2). 18F-FES, representing ER-positive lesions, is a currently FDA approved tracer that can be used in combination with a tumor biopsy to determine ER status in the whole body (10).

- 126 (NCT02453984), including four patients with mTNBC [12]. This study showed that imaging with the
- 127 tracer was feasible and safe. The results indicated clear heterogeneity of expression within and

- 128 between lesions and a promising role as a predictive marker for response to treatment with PD-L1
- 129 antibodies. For the patients with mTNBC in this study, SUVmax was clearly over the SUVmean in the
- 130 blood pool measured over the aorta, with varying levels of SUVmax in different organs. In this study,
- 131 higher SUVmax was related to a better antitumor response, according to RECIST.
- 132
- 133 Here we report the study protocol of the Molecular Imaging to Monitor Immune Responses in mTNBC
- 134 (MIMIR-mTNBC; EU CT 2022-500808-21-00, NCT05742269) trial. In this phase II diagnostic imaging
- 135 study, we aim to evaluate the role of ⁸⁹Zr-atezolizumab PET/CT as a way to refine the group of patients
- 136 with mTNBC that benefit from the addition of an ICIs to a chemotherapy backbone. The primary
- 137 purpose of the trial is to establish the level of statistical agreement between PD-L1 status by the
- 138 current reference standard with IHC versus PET with ⁸⁹Zr-atezolizumab. Our hypothesis is that Positron
- 139 Emission Tomography combined with Computed Tomography (PET/CT) imaging with a contemporary
- 140 radiotracer (⁸⁹Zr-atezolizumab), visualizing PD-L1 expression in the whole body, could be a better
- 141 predictive biomarker to select which patients benefit from ICI.
- 142

143

144

145

147 Materials and methods

148 To test this hypothesis, we are performing a phase II PD-L1 PET/CT imaging study with ⁸⁹Zr-

- 149 atezolizumab in patients with mTNBC. The study design is summarized as SPIRIT schedule of
- 150 enrolment, interventions and assessments in Figure 1. A graphical representation of the study design
- is presented in Figure 2.
- 152

153 Study setting

- 154 Our target population consists of patients with mTNBC scheduled for first line palliative systemic
- 155 treatment with nab-paclitaxel and carboplatin. This chemotherapy combination is used to maximize
- 156 the therapeutic potential of this first line systemic treatment line, extrapolating signals from early

157 TNBC (13) and in the absence of signs that indicate augmented safety issues (14).

- 158 Patients will be recruited at Karolinska University Hospital in Stockholm, Sweden. Additional Swedish
- 159 study sites are planned to be added. The study-specific investigations with ⁸⁹Zr-atezolizumab PET/CT,
- 160 the study biopsies and blood samples will be done at the respective sites. The ⁸⁹Zr-atezolizumab
- 161 radiotracer will be centrally produced at the Department of Radiopharmacy, Karolinska University
- 162 hospital in Solna, and shipped by courier to the respective sites throughout the country. The PD-L1 IHC
- 163 will be centrally reviewed by the study pathologist that is dedicated to this study and trained and
- 164 certified by Ventana on PD-L1 status assessment using SP142 and IHC. The PET-images will be
- 165 acquired according to a standardized protocol that will be the same throughout all the sites and
- 166 reviewed by a nuclear medicine physician ⁸⁹Zr-atezolizumab radiotracer.
- 167

168 Study population

Patients with metastatic/irresectable triple negative breast cancer are candidates for inclusion in the MIMIR-mTNBC trial, according to the inclusion and exclusion criteria summarized in Table 1. In short, patients must be fit and willing to receive treatment with chemotherapy plus/minus atezolizumab and undergo a tumor biopsy and PET/CT. The tumor localizations have to be measurable according to

173	RECIST v1.1 (14) and a non-skeletal lesion has to be accessible for ultrasound- or CT-directed biopsy.
174	No contra-indications for PET/CT investigations or treatment with atezolizumab must be present.
175	Informed consent is mandatory before randomization and will be obtained by a physician with the
176	appropriate delegation.
177	
178	Experimental investigations
179	Study-related assessments include imaging, laboratory tests (blood, feces and tumour samples) and
180	clinical outcome assessments including treatment response and toxicities, as summarized in the SPIRIT
181	chart in Figure 1.
182	
183	1. Imaging Assessments
184	The participants of the study will undergo one session of 89 Zr-atezolizumab PET/CT (PD-L1 PET in the
185	rest of this manuscript), which is performed within 14 days before initiation of the systemic
186	oncological treatment. Response evaluation after 2 courses of systemic therapy will be performed
187	according to clinical routine with CT of chest and abdomen.
188	
189	⁸⁹ Zr-atezolizumab is administered as a single intravenous injection at the department of Nuclear
190	Medicine. Pre-injection as well as one hour after injection, blood pressure, pulse and temperature are
191	taken by a nurse experienced with the administration of radiotracers. The patient can go home
192	afterwards and will be phoned by the study nurse 48-72 hours later to follow-up clinical status.
193	
194	At 5 days post-injection of ⁸⁹ Zr-atezolizumab, a whole-body PET will be acquired. Imaging will be
195	performed using the same protocol on either a Siemens Biograph mCT PET/CT scanner (Siemens,
196	Erlangen, Germany) or GE Discovery MI, (GE, Milwaukee, WI, USA) at participating sites (according to
197	2.4). The images acquired using PD-L1 PET will be analyzed with image processing software available in

198 the clinic (Syngo.Via, Siemens Healthineers and Software from Hermes Medical Solution AB, Sweden), 199 according to the following steps: 200 1) At the imaging day, a first examination will be done to assess whether ⁸⁹Zr-atezolizumab PD-L1 positive lesions 201 are found. This will be communicated with the study interventional radiologist who then decides the optimal 202 location to obtain the study specific tumor biopsy. 203 204 2) The maximum, peak, and average standardized uptake value (SUVmax, SUV peak, and SUVmean), and Total 205 PD-L1 Positive Volume) will be estimated in the whole-body images acquired and will be analysed after all 206 patients have been included and results for the final analysis are prepared. 207 208 2. Biological material: tumor, blood and feces samples 209 Tumor biopsy for PD-L1: Within 72 hours after the PD-L1 PET scanning, one or more tumour biopsies 210 are obtained from metastatic lesion (-s). Core biopsy needles are used to increase chances to obtain 211 representative material and to minimize the change for sample bias due to spatial heterogeneity in 212 PD-L1 expression. The biopsy is performed by an experienced radiologist and will be image-guided 213 with either ultrasound- or CT-directed modalities. The site of biopsy is determined by the radiologist 214 and guided by the fused images obtained from the PD-L1 PET Investigation. Preferentially, material 215 should be obtained from a lesion that shows PD-L1 positivity. In case of presence of both PD-L1 216 positive and PD-L1 negative lesions at the PD-L1 PET, when technically feasible and deemed safe by 217 the radiologist, material is obtained from both a positive and a negative lesion. When available, 218 material from the primary tumor is retrieved by the pathologist for review and to perform PD-L1 IHC. 219 220 The biopsied material is transported to the pathology department at the hospital where the biopsy is 221 taken and managed according to clinical routine. Material from the primary tumor (when available) is 222 collected. The Ventana SP142 antibody is used to assess PD-L1 status, where PD-L1 positivity is 223 defined as positive PD-L1 expression on \geq 1% of immune cells.

After performing IHC, whole slide PD-L1 stained tissue/core biopsy sections, including a positive and negative control, are scanned by 40x magnification (Hamamatsu or similar), and sent to the study pathologist for central revision.

227

Blood samples: Circulating PD-L1 mRNA: Exosomes are released from normal and from cancer cells, representing the phenotype of their originating cell by their content of RNA, DNA and proteins. PD-L1 gene expression from exosomally derived RNA was performed by Raimondi et al (16), demonstrating that high levels of PD-L1 mRNA expression at baseline were correlated with greater response to atezolizumab plus nab-paclitaxel, and that partial or complete response was positively associated with decrease in mRNA expression and improved overall survival. In our study, exosomal mRNA expression will be performed with the same strategy using the exoRNeasy kit (Qiagen) and Bio-Rad QX100 ddPCR.

235

236 Foundation One Liquid CDx: Material for Foundation One liquid biopsy is collected at baseline and at 237 the first therapy evaluation, 8 weeks after treatment start. FoundationOne CDx™ (Foundation 238 Medicine, Penzberg Germany; FoundationOne Liquid Cdx test) FoundationOne Liquid CDx is a next 239 generation sequencing based in vitro diagnostic device that analyses 324 genes. Substitutions and 240 insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) 241 are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects 242 tumor fraction and the genomic signatures blood tumor mutational burden (bTMB) and microsatellite 243 instability high (MSI-H) status. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) 244 isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. For 245 this sample, a separate informed consent form will be retrieved from the study participant.

246

247 Feces microbiome analyses: Feces samples are collected at baseline and at the first treatment

248 evaluation after two 4-weekly treatment cycles. The aim of this project is to evaluate potential

249 therapy-modifying factors verified from the gut microbiota. Several studies have shown that efficacy

of ICI treatment is influenced by the microbiome, e.g. the gastro-intestinal/colonic bacterial flora (17,
18). Both pre-clinical as well as clinical data have shown that presence of certain forms of microbiome
constitute as well as recent and current use of antibiotics are related to a lack of ICI treatment effect.
Clinical data on antibiotic and proton pump inhibitor use will be monitored.
3. Clinical Outcome Assessments
All patients will undergo a baseline CT of the chest-abdomen to be able to perform a treatment
evaluation after 2 courses (8 weeks) with the systemic therapy as defined above. In addition, routine
blood tests are performed, at the discretion of the treating physician. For the PD-L1+ patients who are
treated with atezolizumab, additional blood tests aimed at measuring toxicity from this drug will be
performed aimed to detect signs of immune-mediated toxicities. A CT/MRI of the brain will be
performed in case of a clinical suspicion for CNS metastases, or when PD-L1 positive lesion(s) are
noted on the baseline PD-L1 PET scan.
Toxicity management, including supportive medication and dose reductions, is done at the discretion
of the treating physician in conjunction with the Principal Investigator and according to the
recommendations in the study protocol.
Outcomes
Objectives and endpoints are summarized in Table 2. The primary endpoint is the concordance
between the current reference standard for PD-L1 testing (IHC on a tumor biopsy) and the
experimental method (PD-L1 PET). Secondary endpoints are related to heterogeneity in PD-L1
receptor expression and the therapy-predictive value of PD-L1 PET. Exploratory endpoints relate to
detection of metastases in sanctuary sites such as the central nervous system, relation with circulating
biomarkers and the possible relation with uptake on PD-L1 PET and the development of immune-
mediated toxicity.

276 Data management

- 277 Data are registered using an electronic Case Report Form (eCRF). Monitoring is performed according
- to Good Clinical Practice (GCP) guidelines. The eCRF provides data on patient demographics, tumor
- biological and treatment characteristics, as well as and data on follow-up. Data are managed by the
- 280 Clinical Trial Office at Centre for Clinical Cancer Studies, Karolinska University Hospital, Stockholm,
- 281 Sweden. Recorded information is pseudonymised. The MIMIR-mTNBC trial is registered at
- www.clinicaltrials.gov (NCT05742269). Ethical permission has been obtained by the Swedish Ethical
- 283 Review Authority and Medical Product Agency (Dnr 5.1.1-2022-73437). All participants must provide
- their written informed consent to participate in this trial.
- 285

286 Follow-up

- 287 The trial ends for each participant followed for 30 days after disease progression but also for
- 288 participants who die, withdraw consent, or are lost to follow-up.
- 289

290 Sample size

- 291 This is an exploratory phase II non-randomized study with the primary aim to assess the statistical
- agreement (by Cohen's kappa coefficient) between the current gold standard (PD-L1 IHC by SP142,
- 293 where PD-L1 positivity is defined as expression \geq 1% on immune cells) and the experimental method
- with PD-L1 PET (PD-L1 positivity is defined as having at least one lesion with radiotracer uptake over
- the background uptake). Approximately 40% of cases are expected to have PD-L1 positivity by means
- of the reference standard with PD-L1 IHC, based on the data from the IMpassion130 and Keynote 355
- trials. We regard a kappa of 0.80 as having a very good statistical agreement; 64 patients are needed
- to be able to estimate the kappa with a precision of +/-0.15.
- 299

300 Statistical methods

301 Continuous data will be summarized using descriptive statistics, where the following parameters will 302 be reported: number of evaluable and missing observations, mean and standard deviation, median, 303 guartiles, and extreme values (minimum and maximum) unless stated otherwise. Categorical data will 304 be presented as number and percentage of subjects. Tests will be two-sided and performed at the 5% 305 significance level unless stated otherwise. All eligible patients will be included in the analysis of the 306 primary, secondary and exploratory objectives. The safety analysis set will contain all subjects who 307 have been exposed to the investigational products ⁸⁹Zr-atezolizumab and atezolizumab. 308 309 Independent safety analysis 310 An Independent Data Monitoring Committee will execute the following monitoring plan and can 311 recommend termination of the study based on the pre-defined stopping criteria. A patient will be 312 withdrawn immediately if she/he withdraws informed consent at her/his own request, unacceptable 313 toxicity occurs, not manageable by symptomatic therapy, dose delay or dose modification, she/he 314 does not comply with the instructions given by the study personnel, pregnancy occurs, the medication 315 has to be discontinued for medical reasons, including severe side effects, other disease, need of other 316 cancer treatment. Patients who have been withdrawn will continue to be tracked and assessed (unless 317 the patient explicitly declines). Entire trial: The study can be stopped due to Adverse Events whose 318 frequency, severity or gravity justify discontinuation, as determined by the Principal Investigators.

319

320 Time plan

321 Recruitment will commence March 2023 at the Karolinska Comprehensive Cancer Centre, Sweden.

322 Further participating sites will be added according to interest and need. Patient enrolment is

setimated to be completed by the end of 2025, and first results on the primary endpoint are reportedin 2026.

325

326 Discussion

327 The current standard of care for treatment of metastatic or irresectable triple negative breast cancer

- 328 is the combination of ICIs with a chemotherapy backbone for patients with a PD-L1 positive tumor
- biopsy with the SP142 (for atezolizumab) or 2CC3 IHC antibodies (pembrolizumab) (1-4), leading to an
- improved overall survival compared to chemotherapy alone.
- 331 There is a clear clinical need to improve the selection of patients for this treatment combination to
- optimize the risk-benefit balance at an individual and societal level, as several downsides exist with the
- 333 currently used reference standard therapy-predictive biomarker of PD-L1 IHC. This relates amongst
- 334 others to the need for invasive tumor biopsies which are burdensome for patients and sometimes
- 335 practically not feasible, the discordance in PD-L1 status between (different sites of) metastases and
- primary tumors and the limited representation of the results of a tumor biopsy from a solitary disease
- 337 localisation compared to the whole-body burden of disease.
- 338 PET-imaging with tracers representing the targets of treatment is a possible way to evade these
- 339 limitations and enables a real-time assessment of the target expression in the whole body which can
- be repeated when needed.
- 341 ⁸⁹Zr-atezolizumab is the first radiolabelled PD-L1 PET-tracer that has been evaluated. Warranting
- 342 results from the first in human study provide the rationale for the MIMIR-mTNBC trial, where we
- 343 hypothesize that PD-L1 PET imaging with ⁸⁹Zr-atezolizumab may be a more reliable and patient-
- 344 friendly alternative to the current reference standard with PD-L1 IHC on a tumor biopsy. In addition,
- 345 studying whole body expression of PD-L1 is thought to provide an enhanced insight in tumor biology
- 346 and development of response to treatment as well as immune-mediated toxicity. This was very
- 347 recently very elegantly shown in a clinical trial with a ⁸⁹Zr-labeled CD8 tracer ⁸⁹ZrED88082A, where a
- 348 CD8-PET was done prior to and after 30 days of treatment with ICI (19). An enormous heterogeneity in
- 349 CD8⁺ T cell distribution and pharmacodynamics within and between patients was noted, revealing and
- 350 visualizing the effects of ICIs on T-cell recruitment throughout the body.
- 351 A few trials with ⁸⁹Zr-atezolizumab have been initiated, according to a search at the website
- 352 Clinicaltrials.gov (searched February 14th 2023); NCT04006522 in patient with metastatic renal cell

353 carcinoma, NCT03850028 in patients with malignant lymphomas and NCT05404048 in patients

treated with CAR T-cell therapy. One imaging sub-study to a clinical trial in patients with metastatic

355 Iobular breast cancer with ⁸⁹Zr-atezolizumab has been registered at clinicaltrials.gov (NCT04222426);

the main study was terminated after including only one patient.

357 Several imaging trials with other radiolabelled PD-L1 and PD-1 antibodies are currently ongoing in

different patient cohorts; ⁸⁹Zr-pembrolizumab (active trials: NCT02760225, NCT03065764), ⁸⁹Zr-

359 durvalumab (NCT03610061, NCT03829007) and ⁸⁹Zr-avelumab (NCT03514719).

360

Taken together, PET-imaging of PD-L1 and PD1 expression as well as other mediators in the response to ICIs may augment insights in the mechanisms of response to these drugs. In addition, this may provide a real-time whole-body assessment of the target of treatment and thereby be used as a therapy-predictive biomarker. The results of the MIMIR-mTNBC may add in the body of evidence of this area, with the prime focus to investigate whether the PD-L1 status by PET correlates to the PD-L1 status determined with IHC on a tumor biopsy, which is the current standard of care for patients with

367 mTNBC.

368

369 In conclusion, in the MIMIR-mTNBC trial, we aim to compare the level of statistical agreement 370 between the current reference standard to assess PD-L1, i.e., on a tumor biopsy by means of IHC, to 371 the experimental method of PD-L1 PET imaging with ⁸⁹Zr-atezolizumab. Our academic-initiated trial 372 addresses a highly unmet medical need and may open new applications for superior and specific non-373 invasive tumor characterization. If ⁸⁹Zr-atezolizumab PET/CT demonstrates a sensitivity and specificity 374 rate at least equal to the currently used reference method (IHC) it should impact patient management 375 by selecting optimal patients for treatment with ICIs. In addition, such a precision medicine tool will 376 substantially benefit the health economy by reduce cost for expensive therapies in patients without 377 expected benefit and only side effects.

378

379 Acknowledgements

- 380 The study team is thankful for the scientific input from Professor E.G.E. de Vries from the University
- 381 Medical Center in Groningen, the Netherlands and the material support from Roche. The
- 382 administrative support of the Clinical Trials Office at the Karolinska University hospital, Stockholm
- 383 Sweden is greatly acknowledged.

384

386 References

- 387 1. Schmid P, Adams S, Rugo HS et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-
- 388 Negative Breast Cancer. NEJM 2018;379(22):2108-2121.
- 389 2. Emens LA, Adams S, Barrios CH. First-line atezolizumab plus nab-paclitaxel for unresectable,
- 390 locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall
- 391 survival analysis. Ann Oncol 2021 Aug;32(8):983-993.
- 392 3. Cortes J, Cescon JW, Rugo HS et al. Pembrolizumab plus chemotherapy versus placebo plus
- 393 chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-
- 394 negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase
- 395 3 clinical trial. Lancet, 396(10265):1817-1828
- Cortes J, Rugo HS, Cescon DW et al. Pembrolizumab plus Chemotherapy in Advanced Triple Negative Breast Cancer. N Engl J Med 2022; 387:217-226
- 398 5. Paver EC, Cooper WA, Colebatch AJ et al. Programmed death ligand-1 (PD-L1) as a predictive
- 399 marker for immunotherapy in solid tumours: a guide to immunohistochemistry

400 implementation and interpretation. Pathology 2021 Feb;53(2):141-156.

- 401 6. Lu S, Stein JE, Rimm DL et al. Comparison of Biomarker Modalities for Predicting Response to
- 402 PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol.
- 403 2019;5(8):1195-1204.
- 404 7. Chen N, Higashiyama N, Hoyos V. Predictive Biomarkers of Immune Checkpoint Inhibitor
 405 Response in Breast Cancer: Looking beyond Tumoral PD-L1. Biomedicines 2021 Dec
- 406 8;9(12):1863
- 8. Boman C, Zerdes I, Mårtensson K et al. Discordance of PD-L1 status between primary and
 metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2021
 Sep;99:102257.
- 410 9. Schmid P, Cortes J, Pusztai L et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N
 411 Engl J Med 2020; 382:810-821,

- 412 10. Federal Drug Administration, approval Cerianna (18-
- 413 FES) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf Vd
- 414 Donk PP, Kist de Ruijter L, Lub-de Hooge N et al. Molecular imaging biomarkers for immune
- 415 checkpoint inhibitor therapy. Theranostics 2020; 10(4): 1708-1718.
- 416 11. Bensch F, van der Veen EL, Lub-de Hooge MN, et al. 89Zr-atezolizumab imaging as a non-
- 417 invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine,
- 418 2018, 1852-
- 419 12. Bian et al, Survival benefit of platinum-based regimen in early stage triple negative breast
- 420 cancer: A meta-analysis of randomized controlled trials. NPJ Breast Cancer 2021 Dec
- 421 21;7(1):157.
- 422 13. West et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced
- 423 squamous NSCLC (Impower131): results from a randomized phase III trial. Lancet Oncology
- 424 2019 Jul;20(7):924-937
- 425 14. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours:
 426 revised RECIST guideline (version 1.1). Eur J Cancer 2009 Jan;45(2):228-47.
- 427 15. Raimondi L, Spinelli GP, Ciracì P et al. Prediction of Response to Atezolizumab Plus Nab-
- 428 Paclitaxel in Unresectable Locally Advanced Triple Negative Breast Cancer (TNBC): the
- 429 ClinicalUsefulness of PD-L1 mRNA Expression in Plasma-Derived Exosomes. Preprints 2021,
- 430 2021030777 (doi: 10.20944/preprints202103.0777.v1)
- 431 16. Gopalakrishan C, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti-PD-1
- 432 immunotherapy in melanoma patients. Science 2018 Jan 5;359(6371):97-103. d
- 433 17. Zitvogel L, Ma Y, Raoult D et al, The microbiome in cancer immunotherapy: Diagnostic tools
 434 and therapeutic strategies. Science. 2018 Mar 23;359(6382):1366-1370.
- 435 18. Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS et al. Whole-body CD8⁺ T cell
- 436 visualization before and during cancer immunotherapy: a phase 1/2 trial. Nat Med. 2022
- 437 Dec;28(12):2601-2610.

438 Tables and Figures

439 Figure 1. SPIRIT schedule of enrolment, interventions and assessments in the MIMIR-mTNBC trial.

- 441 Abbreviations: programmed death ligand 1 (PD-L1), Positron Emission Tomography with Computed
- 442 Tomography (PET/CT), progressive disease (PD)
- 443

444 Figure 2: Study design of the MIMIR-mTNBC trial.

445

- 446 Abbreviations: metastatic triple negative breast cancer (mTNBC), programmed death ligand 1 (PD-L1),
- 447 Positron Emission Tomography with Computed Tomography (PET/CT), immunohistochemistry (IHC),
- 448 area under the curve (AUC).

450 Table 1. Inclusion and exclusion criteria in the MIMIR-mTNBC trial.

nclusion criteria	Exclusion criteria				
 Age ≥ 18 years Diagnosed with mTNBC (tumor biology: ER<10%, PR<10%, HER2-) Measurable disease according to RECIST v1.1 At least one metastatic lesion accessible for biopsy Deemed by treating physician as fit for systemic therapy according to study protocol ECOG performance score 0 or 1 Adequate blood tests for bone marrow, renal and hepatic functions (Table 6) Able and willing to provide written informed consent 	 Previous treatment with chemotherapy or targeted therapy for mTNBC. Radiation therapy and previous chemotherapy (including taxaness in the context of curative therapy (if treatment was completed ≥12 months before randomization) is allowed. Contraindications for PET/CT as defined for clinical practice Other malignancy within the past five years For women in childbearing age: pregnancy or lactation, or inadequate contraception Uncontrolled hypertension, heart-, liver-, or kidney-diseases or other medical/psychiatric disorders History of autoimmune disease with the exception of controlled hypothyroidism, type 1diabetes mellitus or skin diseases. Treatment with systemic immunosuppressive drugs 				

452

453 Table 2: Objectives and endpoints of the MIMIR-mTNBC trial.

	Objectives	Endpoints				
Primary	Establish the statistical agreement (by means of	Level of statistical agreement by means of Cohen's				
	Cohen's kappa coefficient) between PD-L1 status	kappa coefficient between PD-L1 IHC (positive defined				
	by the experimental method (PET/CT with ⁸⁹ Zr-	as expression ≥1% on immune cells with SP142) and				
	atezolizumab) and the current reference	PD-L1 PET/CT (PD-L1 positivity is defined as having at				
	standard (IHC on a tumor biopsy or resection	least one lesion with radiotracer uptake over the				
	specimen).	background uptake).				
Secondary	Evaluate the therapy-predictive value of ⁸⁹ Zr-	Progression free survival, disease response rate and				
	atezolizumab PET/CT, compared to the current	treatment discontinuation rates in three patient				
	reference standard (PD-L1 IHC) for treatment	groups				
	with nab-paclitaxel, carboplatin + atezolizumab.	IHC positive and PET positive,				
	Three patient groups are defined, and treatment	IHC positive and PET negative,				
	outcomes (progression free survival, disease	IHC negative and PET positive.				
	response rate, treatment discontinuation rates)					
	will be compared:					
	1) IHC positive and PET positive,					
	2) IHC positive and PET negative,					
	3) IHC negative and PET positive.					
	Investigate inter- and intra-lesional differences in	Discordance in ⁸⁹ Zr-atezolizumab between different				
	PD-L1 positivity by ⁸⁹ Zr-atezolizumab radiotracer	sites and within metastatic sites in the body.				
	uptake					
	Investigate the therapeutic role of atezolizumab	Progression free survival, disease response rate and				
	for ER-low, PD-L1 positive breast cancer (ER	treatment discontinuation rates in patients with ER-				
	expression 1-10%).	low mBC treated with nab-paclitaxel, carboplatin and				
		atezolizumab.				
	Investigate the possible role of ⁸⁹ Zr-atezolizumab	Percentage of ⁸⁹ Zr-atezolizumab uptake in sites, not				
	PET/CT as a method of detecting otherwise (with	previously determined on the routine radiological				
	regular CT-chest-abdomen) occult metastatic	investigation with CT, as a measure of cancer spread				
	sites including sanctuary sites such as the central	determined on whole body ⁸⁹ Zr-atezolizumab PET/CT				
	nervous system (CNS)	in and different metastases.				
Exploratory	Explore mechanisms for possible discordance	Differences in immune infiltrate and tumor cells in				
	between PD-L1 positivity by IHC and ⁸⁹ Zr-	biopsied sites with discordance between PD-L1 IHC				
	atezolizumab radiotracer uptake on PET/CT	and PD-L1 PET				
	Study the genetic profile of circulating (fractions	Levels and composition of circulating biomarkers and				
	of) tumour cells to predict treatment responses	relation to treatment response (PFS, disease response				
	and monitor changes in biological behaviour by	rate) and PD-L1 positivity by PET and IHC				
	means of ctDNA assessed by Foundation One					
	liquid biopsies CDx-analysis at baseline and at	- Levels of circulating PD-L1 mRNA				
	the first treatment evaluation, with a specific	- Gene expression signals in liquid biopsies				
	focus on identifying patients with an enriched					
	'Immunotherapy pathway' in relation to PD-L1					
	status on PET and IHC and levels of circulating					
	PD-L1 mRNA measured in exosomes at baseline					
	and the first treatment evaluation					
	Explore off-target effects of ICI by means of	Rates (and severity according to CTC-AE) of immune-				
	studying ⁸⁹ Zr-atezolizumab radiotracer uptake in	mediated side effects in relation to ⁸⁹ Zr-atezolizumab				
	organs at risk for immune-mediated toxicities as	tracer uptake in organs at risk for immune-mediated				
	well as studying the composition of and changes	toxicities.				
	in the intestinal microbiome.					

	STUDY PERIOD							
	Enrolment	Allocation	Post-allocation				Close-out	
TIMEPOINT (weeks)	-(1-2)	0	8	16	24	8-weekly during treatment	Disease progression	Within 30 days after PD
ENROLMENT:								
Eligibility screen	х							
Informed consent	х							
89Zr-atezolizumab tracer injection	x							
PET/CT image acquisition	X (5 days post-injection)							
Tumor biopsy	X (48 hours after PET)							
INTERVENTIONS:								
Treatment allocation according to PD-L1 status (chemo backbone +/- atezolizumab)		× +						
ASSESSMENTS:								
PD-L1 status (primary endpoint)		x						
CT-thorax-abdomen (RECIST v1.1)				x	х	x	x	
Sample collection (blood, feces)			x	x				
Treatment-related toxicities				x	x	x	x	
Survival								x

MIMIR-mTNBC

